[{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Composition of Matter Patent in China Expands ONC201\u2019s Global Coverage","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase I\/II Clinical Study of ONC201 Begins in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncoceutics to Present Additional Data at ASCO Showing Clinical Benefit from ONC201 for Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Rare Pediatric Disease Designation to ONC201 for the Treatment of H3 K27M-Mutant Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Pacific Pediatric Neuro-Oncology Consortium","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"ONC-201","moa":"Dopamine","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pacific Pediatric Neuro-Oncology Consortium","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pacific Pediatric Neuro-Oncology Consortium \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Pacific Pe.."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Chimerix","pharmaFlowCategory":"D","amount":"$78.0 million","upfrontCash":"$39.0 million","newsHeadline":"Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"ONC201","moa":"DRD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Chimerix","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Pacific Pediatric Neuro-Oncology Consortium","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PNOC Study in Childhood Brain Cancer Enrols First Patient","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kazia Therapeutics \/ Pacific Pediatric Neuro-Oncology Consortium","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Chimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ONC201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/.."}]
Find Clinical Drug Pipeline Developments & Deals for 11-BENZYL-7-[(2-METHYLPHENYL)METHYL]-2,5,7,11-TETRAAZATRICYCLO[7.4.0.0(2),?]TRIDECA-1(9),5-DIEN-8-ONE
Details :
ONC201 is a new drug candidate that kills cancer cells but not normal cells in laboratory studies and has been previously evaluated in a phase I clinical trial in advanced cancer patients.
Details :
At the outset, all patients will be treated with ONC201, combined with either paxalisib or panobinostat. The study employs an adaptive design, in which different arms will be opened and closed based on em...
Details :
ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist in late-stage clinical development for recurrent gliomas that harbor the H3 ...
Details :
Kazia Therapeutics has executed a Letter of Intent with the Pacific Pediatric Neuro-Oncology Consortium to launch a clinical trial of multiple therapies, including Kazia's investigational, paxalisib, in d...
Details :
Should ONC201 be approved by the FDA for H3 K27M-mutant glioma, the Rare Pediatric Disease Designation may enable Oncoceutics to receive a Rare Pediatric Disease Priority Review Voucher.
Details :
Clinical trial provides Japanese patients with high-grade glioma immediate access to ONC201. Data from this study will be an important part of working toward a Japanese market approval for ONC201.
Details :
With these new patents, Oncoceutics has more than 20 patents for ONC201 issued globally with 10 patents for ONC201 issued by the United States Patent Office.
Market Place
Reset All
